NOSOPHARM AND GNA NOW ANNOUNCE POSITIVE RESULTS FOR THE LATE PRECLINICAL DEVELOPMENT OF THE FIRST-IN-CLASS ANTIBIOTIC NOSO-502 

An important milestone has been reached for the GNA NOW Consortium with the completion of the GLP toxicology studies for the NOSO-502 program. The results allow for the further development of the program to Phase 1  Utrecht, the Netherlands, and Lyon, France, 8 June 2022  Nosopharm, a biotechnology company specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces the completion and positive results of toxicology studies for

learn more